Updates
** Shares of drug developer Altimmune ALT.O fall as much as 62.4% to a near two-year low of $2.90
** Stock set for its biggest one-day pct. drop ever, if losses hold
** Co says its experimental obesity drug, pemvidutide, helped patients with a type of fatty liver disease achieve disease resolution without worsening of liver scarring in a mid-stage study
** However, the drug does not show statistically significant improvement in liver scarring or fibrosis in patients with the condition, metabolic dysfunction-associated steatohepatitis (MASH) - ALT
** While the overall data looks good, "missing on statistical significance for fibrosis will be hard for investors to look past" says Citzensbank analyst Jonathan Wolleben
** "We believe the results are underwhelming...view the weight-loss magnitude at 24 weeks as non-differentiating" - William Blair analyst Andy Hsieh
** There's a limited ability to demonstrate stringent scarring improvement at the 48-week time point - Hsieh
** Including session's move, stock down 51.8% YTD
(Reporting by Mariam Sunny and Puyaan Singh in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.